Chung Yin Kong

Chung Yin Kong

Auto-generated profile, based on publicly available information

Chung Yin Kong

Division of General Internal Medicine Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2019 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SCSteven D Criss
Steven D Criss
PCPianpian Cao
Pianpian Cao
MBMehrad Bastani
Mehrad Bastani
KHKevin Ten Haaf
Kevin Ten Haaf
YCYufan Chen
Yufan Chen
CKChung Yin Kong
Chung Yin Kong
Recommendations vary regarding the maximum age at which to stop lung cancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74 years according to the National Lung Screening Trial (NLST). To compare the cost-effectiveness of different stopping ages for lung cancer screening. By using shared inputs for smoking behavior, costs, and quality of life, 4 independently developed microsimulation models evaluated the health and cost outcomes of annual lung cancer screening with low-dose computed tomography (LDCT). The NLST; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SEER (Surveillance, Epidemiology, and End Results) program; Nurses' Health Study and Health Professionals Follow-up Study; and U.S. Smoking History Generator. Current, former, and never-smokers aged 45 years from the 1960 U.S. birth cohort. 45 years. Health care sector. Annual LDCT according to NLST, CMS, and USPSTF criteria. Incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $100 000 per quality-adjusted life-year (QALY). The 4 models showed that the NLST, CMS, and USPSTF screening strategies were cost-effective, with ICERs averaging $49 200, $68 600, and $96 700 per QALY, respectively. Increasing the age at which to stop screening resulted in a greater reduction in mortality but also led to higher costs and overdiagnosis rates. Probabilistic sensitivity analysis showed that the NLST and CMS strategies had higher probabilities of being cost-effective (98% and 77%, respectively) than the USPSTF strategy (52%). Scenarios assumed 100% screening adherence, and models extrapolated beyond clinical trial data. All 3 sets of lung cancer screening criteria represent cost-effective programs. Despite underlying uncertainty, the NLST and CMS screening strategies have high probabilities of being cost-effective. CISNET (Cancer Intervention and Surveillance Modeling Network) Lung Group, National Cancer Institute.

29 November 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KHKevin Ten Haaf
Kevin Ten Haaf
MBMehrad Bastani
Mehrad Bastani
PCPianpian Cao
Pianpian Cao
JJJihyoun Jeon
Jihyoun Jeon
ITIakovos Toumazis
Iakovos Toumazis
HKHarry de Koning
Harry de Koning
Background: Risk-prediction models have been proposed to select individuals for lung cancer screening. However, their long-term effects are uncertain. This study evaluates long-term benefits and harms of risk-based screening compared with current United States Preventive Services Task Force (USPSTF) recommendations. Methods: Four independent natural history models were used to perform a comparative modeling study evaluating long-term benefits and harms of selecting individuals for lung cancer screening through risk-prediction models. In total, 363 risk-based screening strategies varying by screening starting and stopping age, risk-prediction model used for eligibility (Bach, PLCOm2012, or Lung Cancer Death Risk Assessment Tool [LCDRAT]), and risk threshold were evaluated for a 1950 US birth cohort. Among the evaluated outcomes were percentage of individuals ever screened, screens required, lung cancer deaths averted, life-years gained, and overdiagnosis. Results: Risk-based screening strategies requiring similar screens among individuals ages 55–80 years as the USPSTF criteria (corresponding risk thresholds: Bach = 2.8%; PLCOm2012 = 1.7%; LCDRAT = 1.7%) averted considerably more lung cancer deaths (Bach = 693; PLCOm2012 = 698; LCDRAT = 696; USPSTF = 613). However, life-years gained were only modestly higher (Bach = 8660; PLCOm2012 = 8862; LCDRAT = 8631; USPSTF = 8590), and risk-based strategies had more overdiagnosed cases (Bach = 149; PLCOm2012 = 147; LCDRAT = 150; USPSTF = 115). Sensitivity analyses suggest excluding individuals with limited life expectancies (<5 years) from screening retains the life-years gained by risk-based screening, while reducing overdiagnosis by more than 65.3%. Conclusions: Risk-based lung cancer screening strategies prevent considerably more lung cancer deaths than current recommendations do. However, they yield modest additional life-years and increased overdiagnosis because of predominantly selecting older individuals. Efficient implementation of risk-based lung cancer screening requires careful consideration of life expectancy for determining optimal individual stopping ages.

21 December 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
DSDeirdre F. Sheehan
Deirdre F. Sheehan
SCSteven D Criss
Steven D Criss
YCYufan Chen
Yufan Chen
AEAndrew Eckel
Andrew Eckel
LPLauren Palazzo
Lauren Palazzo
CKChung Yin Kong
Chung Yin Kong
Background: We studied trends in lung cancer treatment cost over time by phase of care, treatment strategy, age, stage at diagnosis, and histology.Methods: Using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database for years 1998‐2013, we allocated total and patient‐liability costs into the following phases of care for 145 988 lung cancer patients: prediagnosis, staging, surgery, initial, continuing, and terminal. Patients served as self‐controls to determine cancer‐attributable costs based on individual precancer diagnosis healthcare costs. We fit linear regression models to determine cost by age and calendar year for each stage at diagnosis, histology, and treatment strategy and presented all costs in 2017 US dollars.Results: Monthly healthcare costs prior to lung cancer diagnosis were $861 for a 70 years old in 2017 and rose by an average of $17 per year (P < 0.001). Surgery in 2017 cost $30 096, decreasing by $257 per year (P = 0.007). Chemotherapy and radiation costs remained stable or increased for most stage and histology groups, ranging from $4242 to $8287 per month during the initial six months of care. Costs during the final six months of life decreased for those who died of lung cancer or other causes.Conclusions: Cost‐effectiveness analyses of lung cancer control interventions in the United States have been using outdated and incomplete treatment cost estimates. Our cost estimates enable updated cost‐effectiveness analyses to determine the benefit of lung cancer control from a health economics point of view.

1 November 2019 in Radiology
Verified
Journal Article
Closed access
MHMark M. Hammer
Mark M. Hammer
LPLauren L. Palazzo
Lauren L. Palazzo
CKChung Yin Kong
Chung Yin Kong
AHAndetta R. Hunsaker
Andetta R. Hunsaker
Subsolid nodules in Lung Imaging Reporting and Data System (Lung-RADS) categories 2 and 3 have a higher risk of malignancy than reported, and ground-glass nodules measuring 10–19 mm have a risk tha... Background Subsolid pulmonary nodules, comprising pure ground-glass nodules (GGNs) and part-solid nodules (PSNs), have a high risk of indolent malignancy. Lung Imaging Reporting and Data System (Lu...

4 September 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SCSteven D Criss
Steven D Criss
MMMeghan J. Mooradian
Meghan J. Mooradian
TWTina R. Watson
Tina R. Watson
JGJustin F. Gainor
Justin F. Gainor
KRKerry L. Reynolds
Kerry L. Reynolds
CKChung Yin Kong
Chung Yin Kong
Immune checkpoint inhibitors (ICIs) have swiftly become the standard of care for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). For several years, ICIs were the therapy of choice for second-line treatment, with atezolizumab, pembrolizumab, and nivolumab—each a programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor—being the predominant options for patients with nonsquamous NSCLC who had been treated previously with chemotherapy.1-3 Given their success as second-line treatments, ICIs were subsequently used as first-line treatments with 2 strategies: ICI monotherapy and ICI in combination with chemotherapy.

1 March 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ITIakovos Toumazis
Iakovos Toumazis
PCPianpian Cao
Pianpian Cao
KNKoen de Nijs
Koen de Nijs
MBMehrad Bastani
Mehrad Bastani
VMVidit Munshi
Vidit Munshi
SHSummer S. Han
Summer S. Han
In its 2021 update of lung cancer screening recommendations, the U.S. Preventive Services Task Force (USPSTF) evaluated strategies that selected people on the basis of risk and emphasized the need ... Visual A Cost-Effectiveness Analysis of Risk Model–Based Lung Cancer Screening. In its 2021 update of lung cancer screening recommendations, the U.S. Preventive Services Task Force (USPSTF... Background: In their 2021 lung cancer screening recommendation update, the U.S. Preventive Services Task Force (USPSTF) evaluated strategies that select people based on their personal lung cancer r...